DXB Dimerix Limited
Healthcare · Biotechnology
· website
· 15 employees
$0.23
52wk 0.16 – 0.67
Overall
41.2
Value
83.2
Growth
0.0
Health
100.0
Quality
0.0
Momentum
2.8
Dividend
—
Price
About Dimerix Limited
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease; as well as DMX-652 for the treatment of acute kidney injury. The company is headquartered in Fitzroy, Australia.
Price analytics
Returns
| 1 day | -4.3% |
| 1 week | 0.0% |
| 1 month | -22.4% |
| 3 months | -11.8% |
| 6 months | -35.7% |
| 1 year | -57.1% |
| 3 years | 32.4% |
Risk
| Volatility (1y ann.) | 81.5% |
| Beta vs ASX 200 | 1.31 |
| Sharpe (1y) | -0.65 |
| VaR 95% (1-day) | -6.5% |
| Max drawdown (1y) | -73.6% |
| Off 1-year high | -64.0% |
Technicals
| RSI(14) | 40 |
| vs 50DMA | -15.8% |
| vs 200DMA | -31.5% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
83.2
Trailing P/E
—
Forward P/E
100
PEG ratio
91
EV / EBITDA
100
Price / Book
100
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
2.8
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
13
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$135.09M
P/E (trailing)
—
P/E (forward)
-11.25
EPS (trailing)
-0.05
Dividend yield
—
Payout ratio
0.0%
Beta
0.34
EV / EBITDA
-3.39
Price / Book
-9.00
ROE
—
Operating margin
-317.5%
Net margin
0.0%
Total cash
$16.15M
Total debt
$232,091
Current ratio
3.82
Debt / Equity
—
Free cash flow
$-48.46M
Avg volume
1.35M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$4.35M
- Gross profit$4.35M
- Operating income-$37.18M
- Net income-$29.81M
- Diluted EPS—
- Free cash flow-$51.81M
- Net debt-$15.92M